TN2009000521A1 - Rnai inhibition of alpha-enac expression - Google Patents

Rnai inhibition of alpha-enac expression

Info

Publication number: TN2009000521A1
Authority: TN; Tunisia
Prior art keywords: alpha; enac expression; rnai inhibition; enac; expression
Prior art date: 2007-06-15

Application number

TNP2009000521A

Other languages

English (en)

Inventor

Heeke Gino Van

Emma Hickman

Henry Luke Danahay

Pamela Tan

Anke Geick

Hans-Peter Vornlocher

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-15

Filing date

2009-12-11

Publication date

2011-03-31

2009-12-11 Application filed by Novartis Ag filed Critical Novartis Ag

2011-03-31 Publication of TN2009000521A1 publication Critical patent/TN2009000521A1/fr

Links

108091030071 RNAI Proteins 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 abstract 2
101710194189 Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000003828 downregulation Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2009000521A 2007-06-15 2009-12-11 Rnai inhibition of alpha-enac expression TN2009000521A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07110376		2007-06-15
EP07114265		2007-08-13
PCT/EP2008/057476 WO2008152131A2 (fr)	2007-06-15	2008-06-13	Inhibition par arni de l'expression du canal alpha-enac

Publications (1)

Publication Number	Publication Date
TN2009000521A1 true TN2009000521A1 (en)	2011-03-31

Family

ID=40130244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000521A TN2009000521A1 (en)	2007-06-15	2009-12-11	Rnai inhibition of alpha-enac expression

Country Status (26)

Country	Link
US (12)	US7718632B2 (fr)
EP (7)	EP2223695B1 (fr)
JP (6)	JP5485146B2 (fr)
KR (2)	KR101821081B1 (fr)
CN (1)	CN101778941B (fr)
AR (1)	AR066984A1 (fr)
AU (1)	AU2008263876B2 (fr)
BR (1)	BRPI0813680A8 (fr)
CA (1)	CA2690674C (fr)
CL (1)	CL2008001756A1 (fr)
CO (1)	CO6251331A2 (fr)
CR (1)	CR11136A (fr)
CU (1)	CU23774A3 (fr)
EA (1)	EA200901653A1 (fr)
EC (1)	ECSP099794A (fr)
ES (6)	ES2432532T3 (fr)
GT (1)	GT200900315A (fr)
IL (1)	IL202366A0 (fr)
MA (1)	MA31564B1 (fr)
MX (1)	MX2009013609A (fr)
PE (1)	PE20090942A1 (fr)
SG (3)	SG169988A1 (fr)
SV (1)	SV2009003434A (fr)
TN (1)	TN2009000521A1 (fr)
TW (3)	TWI552753B (fr)
WO (1)	WO2008152131A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1532248B1 (fr)	2002-07-26	2009-04-01	Novartis Vaccines and Diagnostics, Inc.	Petites molecules modifiees d'arn d'interference et leurs procedes d'utilisation
KR100473148B1 (ko) *	2002-11-27	2005-03-10	(주)텔리언	버스트모드 패킷 전달을 위한 정합장치 및 방법
CA2581651C (fr) *	2004-10-01	2014-12-16	Novartis Vaccines And Diagnostics, Inc.	Arn modifie marque avec du cholesterol
US8765704B1 (en)	2008-02-28	2014-07-01	Novartis Ag	Modified small interfering RNA molecules and methods of use
AR066984A1 (es)	2007-06-15	2009-09-23	Novartis Ag	Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2010062817A1 (fr) *	2008-11-26	2010-06-03	Merck Sharp & Dohme Corp.	Inhibition véhiculée par arn interférence de l’expression du gène de canal sodique épithélial (enac) utilisant un acide nucléique interférant court (ansi)
CN103275978B (zh) *	2009-04-03	2014-10-29	百奥迈科生物技术有限公司	修饰的小干扰核酸及其制备方法
EP2415869A4 (fr) *	2009-04-03	2013-06-19	Biomics Biotechnologies Co Ltd	Molécule modifiée d'acide oligo-nucléique, procédé d'élaboration et utilisations de celle-ci
EP2756845B1 (fr) *	2009-04-03	2017-03-15	Dicerna Pharmaceuticals, Inc.	Procédés et compositions pour l'inhibition spécifique de KRAS par de l'ARN double brin asymétrique
US20120207818A1 (en) *	2009-07-14	2012-08-16	Shinohara Fumikazu	Composition for suppressing expression of target gene
AU2010306940A1 (en) *	2009-10-12	2012-06-07	Smith, Larry	Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US8293718B2 (en)	2009-12-18	2012-10-23	Novartis Ag	Organic compositions to treat HSF1-related diseases
US8344127B2 (en)	2010-04-23	2013-01-01	Novartis Ag	Organic compositions to treat beta-ENaC-related diseases
CN103703141B (zh) *	2011-04-08	2016-08-17	伯乐实验室公司	具有降低的非特异性活性的pcr反应混合物
JP2014519806A (ja)	2011-04-20	2014-08-21	スミスホールディングス，エルエルシー	細胞内で自己会合し、ＲＮＡｉ活性を産生する組成物を使用した遺伝子発現を調節するための方法および成分
KR102540778B1 (ko) *	2011-06-21	2023-06-07	알닐람 파마슈티칼스 인코포레이티드	아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
EP2751272A2 (fr)	2011-09-02	2014-07-09	Novartis AG	Compositions organiques de traitement de maladies associées à hsf1
DK3535397T3 (da)	2016-11-01	2022-01-31	Arrowhead Pharmaceuticals Inc	Alfa-v-beta-6-integrin-ligander og anvendelser deraf
CN119662650A (zh)	2017-07-06	2025-03-21	箭头药业股份有限公司	用于抑制α-ENaC表达的RNAi剂及使用方法
KR20200079505A (ko) *	2017-10-31	2020-07-03	아이오니스 파마수티컬즈, 인코포레이티드	ENaC 발현의 조절제
EP3703700A4 (fr) *	2017-11-01	2021-08-04	Arrowhead Pharmaceuticals, Inc.	Ligands d'intégrine et utilisations de ces derniers
CN109364248B (zh) *	2018-10-16	2021-05-18	哈尔滨医科大学	ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
WO2021041776A1 (fr) *	2019-08-30	2021-03-04	United States Government As Represented By The Department Of Veterans Affairs	Formulations liposomales de composés troponoïdes
US12415840B2 (en)	2020-02-21	2025-09-16	Brookhaven Science Associates, Llc	Modified form of oleosin that when expressed in plants leads to increased triacylglycerol (oil) accumulation
US11957178B2 (en)	2021-11-15	2024-04-16	Apackaging Group Llc	Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4534899A (en)	1981-07-20	1985-08-13	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4426330A (en)	1981-07-20	1984-01-17	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) *	1985-10-03	1989-06-06	Rajakhyaksha Vithal J	Transdermal and systemic preparation and method
DE3604625C2 (de) *	1986-02-14	1994-01-20	Bmw Rolls Royce Gmbh	Gasturbine
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US5451670A (en) *	1987-12-09	1995-09-19	City Of Hope	Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en)	1988-10-20	1988-11-23	Royal Free Hosp School Med	Liposomes
US5013566A (en) *	1988-12-19	1991-05-07	Sampson Michael James	Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5356633A (en)	1989-10-20	1994-10-18	Liposome Technology, Inc.	Method of treatment of inflamed tissues
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
US5665710A (en)	1990-04-30	1997-09-09	Georgetown University	Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja)	1991-05-23	2001-10-22	三菱化学株式会社	薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja)	1993-01-22	2002-11-25	三菱化学株式会社	リン脂質誘導体及びそれを含有するリポソーム
DE69422163T2 (de)	1993-02-19	2000-06-15	Nippon Shinyaku Co., Ltd.	Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung
US5395619A (en)	1993-03-03	1995-03-07	Liposome Technology, Inc.	Lipid-polymer conjugates and liposomes
CA2137297C (fr)	1993-12-06	2000-04-18	Tsuyoshi Miyazaki	Vesicule reactive et vesicule fonctionnelle fixee a une substance
JP3543347B2 (ja) *	1994-01-24	2004-07-14	日本油脂株式会社	点火薬造粒物の製造方法
US5543152A (en)	1994-06-20	1996-08-06	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5820873A (en)	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en)	1995-06-07	1998-05-26	Georgetown University	Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
AU705644B2 (en)	1995-08-01	1999-05-27	Novartis Ag	Liposomal oligonucleotide compositions
US5858397A (en)	1995-10-11	1999-01-12	University Of British Columbia	Liposomal formulations of mitoxantrone
US5998203A (en)	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en)	1996-02-21	1999-11-30	The Immune Response Corporation	Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en)	1997-05-16	2001-04-17	Research Corporation Technologies, Inc.	Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) *	1996-08-01	1999-02-02	Wilson-Hyde; Cynthia	Step aerobic platform
AU742598B2 (en)	1997-03-11	2002-01-10	Yale University	Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
WO1999001579A1 (fr)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions et procedes d'apport d'oligonucleotides par le tube digestif
US5976849A (en)	1998-02-05	1999-11-02	Zeneca Limited	Human E3 ubiquitin protein ligase
JP2002537828A (ja)	1999-03-10	2002-11-12	フォゲンリミティド	細胞への物質のデリバリー
CA2429814C (fr) *	2000-12-01	2014-02-18	Thomas Tuschl	Petites molecules d'arn mediant l'interference arn
BR0209646A (pt)	2001-05-16	2006-10-10	Novartis Ag	genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
EP1478655A4 (fr)	2001-12-31	2006-05-10	Algos Therapeutics Inc	Procedes et substances de modulation de l'enac-beta
EP1532248B1 (fr)	2002-07-26	2009-04-01	Novartis Vaccines and Diagnostics, Inc.	Petites molecules modifiees d'arn d'interference et leurs procedes d'utilisation
JP2004121218A (ja)	2002-08-06	2004-04-22	Jenokkusu Soyaku Kenkyusho:Kk	気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en)	2002-08-14	2002-09-25	Creative Peptides Sweden Ab	Fragments of Insulin c-peptide
EP2305812A3 (fr) *	2002-11-14	2012-06-06	Dharmacon, Inc.	SIRNA fonctionnel et hyperfonctionnel
AU2003293124A1 (en)	2002-11-27	2004-06-23	Artesian Therapeutics, Inc.	Heart failure gene determination and therapeutic screening
AU2002368410A1 (en)	2002-11-29	2004-06-23	Basf Aktiengesellschaft	Methods for the production of methionine
DE10305213A1 (de) *	2003-02-07	2004-08-26	Florian Prof. Dr.med. Lang	Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
CA2520016A1 (fr) *	2003-03-31	2004-10-21	University Of Iowa Research Foundation	Therapie pharmaco-genique des troubles associes au canal sodique epithelial
US7723509B2 (en) *	2003-04-17	2010-05-25	Alnylam Pharmaceuticals	IRNA agents with biocleavable tethers
WO2004094636A1 (fr)	2003-04-24	2004-11-04	Galapagos Genomics N.V.	Constructions demontables effectives d'arnsi
US20050256071A1 (en) *	2003-07-15	2005-11-17	California Institute Of Technology	Inhibitor nucleic acids
JP4530335B2 (ja) *	2004-02-03	2010-08-25	独立行政法人科学技術振興機構	膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
KR20070085113A (ko) *	2004-05-11	2007-08-27	가부시키가이샤 알파젠	Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
SE0402832D0 (sv) *	2004-11-18	2004-11-18	Astrazeneca Ab	Methods
US7923206B2 (en) *	2004-11-22	2011-04-12	Dharmacon, Inc.	Method of determining a cellular response to a biological agent
AU2005316384B2 (en) *	2004-12-14	2012-02-09	Alnylam Pharmaceuticals, Inc.	RNAi modulation of MLL-AF4 and uses thereof
JP5336853B2 (ja) *	2005-11-02	2013-11-06	プロチババイオセラピューティクスインコーポレイティッド	修飾ｓｉＲＮＡ分子およびその使用法
WO2007070509A2 (fr) *	2005-12-13	2007-06-21	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Agents inhibiteurs du canal sodium epithelial et utilisations
CA2660842C (fr)	2006-08-18	2012-03-13	F. Hoffmann-La Roche Ag	Polyconjugues pour l'administration in vivo de polynucleotides
JP2010505897A (ja)	2006-10-11	2010-02-25	マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ	インフルエンザターゲット
AR066984A1 (es) *	2007-06-15	2009-09-23	Novartis Ag	Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

2008
- 2008-06-12 AR ARP080102518A patent/AR066984A1/es not_active Application Discontinuation
- 2008-06-13 MX MX2009013609A patent/MX2009013609A/es active IP Right Grant
- 2008-06-13 KR KR1020167023121A patent/KR101821081B1/ko active Active
- 2008-06-13 EP EP10163502.7A patent/EP2223695B1/fr active Active
- 2008-06-13 EP EP10163496.2A patent/EP2224004B1/fr active Active
- 2008-06-13 ES ES10163502T patent/ES2432532T3/es active Active
- 2008-06-13 CN CN2008801032623A patent/CN101778941B/zh active Active
- 2008-06-13 ES ES10163501T patent/ES2432158T3/es active Active
- 2008-06-13 SG SG201101084-0A patent/SG169988A1/en unknown
- 2008-06-13 EP EP10163499.6A patent/EP2223692B1/fr active Active
- 2008-06-13 TW TW103118914A patent/TWI552753B/zh not_active IP Right Cessation
- 2008-06-13 EA EA200901653A patent/EA200901653A1/ru unknown
- 2008-06-13 AU AU2008263876A patent/AU2008263876B2/en not_active Ceased
- 2008-06-13 SG SG10201601846VA patent/SG10201601846VA/en unknown
- 2008-06-13 JP JP2010511658A patent/JP5485146B2/ja active Active
- 2008-06-13 ES ES10163500T patent/ES2432644T3/es active Active
- 2008-06-13 KR KR1020107000840A patent/KR101653008B1/ko active Active
- 2008-06-13 TW TW105120348A patent/TWI629063B/zh not_active IP Right Cessation
- 2008-06-13 EP EP08761002A patent/EP2171059A2/fr not_active Withdrawn
- 2008-06-13 ES ES10163496T patent/ES2432643T3/es active Active
- 2008-06-13 ES ES10163499T patent/ES2432157T3/es active Active
- 2008-06-13 ES ES10163498.8T patent/ES2439277T3/es active Active
- 2008-06-13 CL CL2008001756A patent/CL2008001756A1/es unknown
- 2008-06-13 CA CA2690674A patent/CA2690674C/fr active Active
- 2008-06-13 EP EP10163501.9A patent/EP2223694B1/fr active Active
- 2008-06-13 WO PCT/EP2008/057476 patent/WO2008152131A2/fr active Application Filing
- 2008-06-13 EP EP10163498.8A patent/EP2224005B1/fr active Active
- 2008-06-13 SG SG10201404955RA patent/SG10201404955RA/en unknown
- 2008-06-13 BR BRPI0813680A patent/BRPI0813680A8/pt not_active IP Right Cessation
- 2008-06-13 EP EP10163500.1A patent/EP2223693B1/fr active Active
- 2008-06-13 TW TW097122240A patent/TWI444474B/zh not_active IP Right Cessation
- 2008-06-13 PE PE2008001013A patent/PE20090942A1/es not_active Application Discontinuation
- 2008-06-16 US US12/140,112 patent/US7718632B2/en active Active
2009
- 2009-11-26 IL IL202366A patent/IL202366A0/en unknown
- 2009-12-02 CR CR11136A patent/CR11136A/es not_active Application Discontinuation
- 2009-12-11 CO CO09142201A patent/CO6251331A2/es not_active Application Discontinuation
- 2009-12-11 TN TNP2009000521A patent/TN2009000521A1/fr unknown
- 2009-12-11 GT GT200900315A patent/GT200900315A/es unknown
- 2009-12-11 EC EC2009009794A patent/ECSP099794A/es unknown
- 2009-12-14 SV SV2009003434A patent/SV2009003434A/es unknown
- 2009-12-15 CU CU20090215A patent/CU23774A3/es not_active IP Right Cessation
2010
- 2010-01-06 US US12/683,146 patent/US9074212B2/en active Active
- 2010-01-07 MA MA32484A patent/MA31564B1/fr unknown
- 2010-04-30 US US12/771,518 patent/US7939508B2/en active Active
- 2010-04-30 US US12/771,614 patent/US8168606B2/en not_active Expired - Fee Related
- 2010-04-30 US US12/771,566 patent/US8119612B2/en active Active
- 2010-04-30 US US12/771,470 patent/US7943592B2/en active Active
2014
- 2014-02-19 JP JP2014029519A patent/JP5719047B2/ja not_active Expired - Fee Related
2015
- 2015-03-19 JP JP2015055783A patent/JP6193906B2/ja not_active Expired - Fee Related
- 2015-06-03 US US14/729,104 patent/US9476052B2/en active Active
2016
- 2016-09-09 US US15/260,824 patent/US9914927B2/en active Active
2017
- 2017-08-01 JP JP2017149211A patent/JP6680728B2/ja not_active Expired - Fee Related
2018
- 2018-01-18 US US15/874,396 patent/US10544418B2/en active Active
2020
- 2020-01-24 US US16/752,325 patent/US11208662B2/en active Active
- 2020-03-17 JP JP2020046007A patent/JP7157775B2/ja active Active
2021
- 2021-12-23 US US17/560,475 patent/US20220112505A1/en not_active Abandoned
2022
- 2022-04-05 US US17/713,763 patent/US20220235361A1/en not_active Abandoned
- 2022-10-07 JP JP2022162309A patent/JP2022188234A/ja active Pending

Also Published As

Publication number	Publication date
JP2017222704A (ja)	2017-12-21
ES2432644T3 (es)	2013-12-04
CR11136A (es)	2010-01-20
AU2008263876B2 (en)	2012-04-12
BRPI0813680A8 (pt)	2018-08-28
ES2432532T3 (es)	2013-12-04
US9914927B2 (en)	2018-03-13
US7718632B2 (en)	2010-05-18
US20100216971A1 (en)	2010-08-26
JP2014129373A (ja)	2014-07-10
SV2009003434A (es)	2011-03-23
EP2171059A2 (fr)	2010-04-07
CA2690674C (fr)	2018-09-11
JP5719047B2 (ja)	2015-05-13
JP6193906B2 (ja)	2017-09-06
ES2439277T3 (es)	2014-01-22
CA2690674A1 (fr)	2008-12-18
EP2223693B1 (fr)	2013-07-24
EP2223695B1 (fr)	2013-07-24
TWI629063B (zh)	2018-07-11
ES2432158T3 (es)	2013-12-02
ES2432643T3 (es)	2013-12-04
EA200901653A1 (ru)	2010-06-30
US20220235361A1 (en)	2022-07-28
TW201636027A (zh)	2016-10-16
BRPI0813680A2 (pt)	2015-01-06
TW201524510A (zh)	2015-07-01
EP2223693A1 (fr)	2010-09-01
US20150284726A1 (en)	2015-10-08
US8119612B2 (en)	2012-02-21
JP2015145393A (ja)	2015-08-13
CO6251331A2 (es)	2011-02-21
US11208662B2 (en)	2021-12-28
GT200900315A (es)	2011-10-05
US20100190714A1 (en)	2010-07-29
US20160376599A1 (en)	2016-12-29
US7943592B2 (en)	2011-05-17
MA31564B1 (fr)	2010-08-02
US20100210513A1 (en)	2010-08-19
MX2009013609A (es)	2010-01-20
CL2008001756A1 (es)	2009-02-20
WO2008152131A3 (fr)	2009-05-28
JP2020094063A (ja)	2020-06-18
TWI444474B (zh)	2014-07-11
EP2223695A1 (fr)	2010-09-01
US9476052B2 (en)	2016-10-25
CU23774A3 (es)	2012-02-15
EP2224004A1 (fr)	2010-09-01
EP2224004B1 (fr)	2013-07-24
JP6680728B2 (ja)	2020-04-15
US20180148726A1 (en)	2018-05-31
JP7157775B2 (ja)	2022-10-20
EP2224005A1 (fr)	2010-09-01
TW200911989A (en)	2009-03-16
EP2223692A1 (fr)	2010-09-01
KR20100039335A (ko)	2010-04-15
US7939508B2 (en)	2011-05-10
AR066984A1 (es)	2009-09-23
SG10201601846VA (en)	2016-04-28
PE20090942A1 (es)	2009-08-05
JP2022188234A (ja)	2022-12-20
CN101778941A (zh)	2010-07-14
CN101778941B (zh)	2013-05-22
EP2223694B1 (fr)	2013-07-24
JP5485146B2 (ja)	2014-05-07
WO2008152131A2 (fr)	2008-12-18
US10544418B2 (en)	2020-01-28
US20200157550A1 (en)	2020-05-21
EP2223694A1 (fr)	2010-09-01
US8168606B2 (en)	2012-05-01
IL202366A0 (en)	2011-08-01
US20090156529A1 (en)	2009-06-18
EP2224005B1 (fr)	2013-09-11
BRPI0813680B1 (pt)	2018-02-06
SG10201404955RA (en)	2014-10-30
SG169988A1 (en)	2011-04-29
AU2008263876A1 (en)	2008-12-18
US20100210514A1 (en)	2010-08-19
ES2432157T3 (es)	2013-12-02
EP2223692B1 (fr)	2013-07-24
KR101653008B1 (ko)	2016-08-31
US9074212B2 (en)	2015-07-07
JP2010530369A (ja)	2010-09-09
KR20160105530A (ko)	2016-09-06
KR101821081B1 (ko)	2018-01-23
US20100216972A1 (en)	2010-08-26
US20220112505A1 (en)	2022-04-14
ECSP099794A (es)	2010-01-29
TWI552753B (zh)	2016-10-11

Publication	Publication Date	Title
TN2009000521A1 (en)	2011-03-31	Rnai inhibition of alpha-enac expression
IN2012DN03883A (fr)	2015-09-25
JO3118B1 (ar)	2017-09-20	تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
AU2016204376A1 (en)	2016-07-14	MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2006036916A3 (fr)	2006-07-27	Modulation d'arni d'apob et utilisations correspondantes
MX2012004780A (es)	2012-08-23	Inhibidores de akt.
SG179085A1 (en)	2012-04-27	Pi3 kinase inhibitors and uses thereof
WO2007014077A3 (fr)	2007-12-06	Modulation de l'arni du gene rho-a et utilisations de celle-ci
MX345909B (es)	2017-02-22	Anticuerpos anti-fgfr3 y métodos que los utilizan.
EP4124657A3 (fr)	2023-05-03	Procédés et compositions pour l'inhibition spécifique de kras par de l'arn double brin asymétrique
MX2009005829A (es)	2009-06-16	Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante.
WO2010048358A3 (fr)	2010-10-21	Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
MY173526A (en)	2020-01-31	Novel anti-?5?1 antibodies and uses thereof
GEP20156329B (en)	2015-07-27	CHEMICAL MODIFICATIONS OF miRNA INHIBITORS AND MIMETICS
MX2011014019A (es)	2012-02-22	Derivados de diazahomoadamantano y sus metodos de uso.
WO2010045384A3 (fr)	2010-06-10	Arn courts en épingles à cheveux destinés à inhiber l’expression des gènes
UA103197C2 (uk)	2013-09-25	Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
AU2018256632A1 (en)	2018-11-22	RNAi inhibition of alpha-ENaC expression
UA97521C2 (ru)	2012-02-27	и-РНК-АГЕНТ, КОТОРЫЙ ОПОСРЕДУЕТ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
WO2006081192A3 (fr)	2009-04-23	Modulation arni du gene nogo-l ou nogo-r et utilisations
EA201071163A1 (ru)	2011-04-29	Применение дефенсинов против менингита
MX2009010812A (es)	2009-10-29	Derivados 4-dodeceno como ingredientes aromatizantes.
UA34487U (en)	2008-08-11	Aquananomagnesium
UA36194U (en)	2008-10-10	Use of quercetin as hepatoprotector
MX2010007695A (es)	2010-08-11	Medios resistentes a abrasion.